venting the occurrence of fractures -or new fracturesin patients presenting with a bone mass or a microarchitecture quality below the norm, on the other hand. The fracture risk increases gradually in function of a decreasing bone mineral content. By consensus, this risk is considered to be unacceptably high when the bone mass is lower than the 90 th percentile of the distribution of values measured in an osteoporotic population, which corresponds, in practice, to a value more than 2.5 standard deviations below the peak bone mass in 25 to 35 years old women.
CALCIUM
In elderly children and adolescents with an equilibrated nutrition, the daily nutritional calcium supply should amount to at least 1200 mg. The usefulness of administration of calcium supplements during the period of growth has not been established. In women before menopause, the daily calcium requirements amount to at least 800 mg. The daily calcium requirements in postmenopausal women under adequate hormonal therapy are the same as in the premenopause.
In postmenopausal women who are not under hormonal replacement therapy, administration of calcium supplements, ensuring a total supply of at least 1500 mg, exert a partial protective effect on the loss of bone mass. Such a partial protective effect has been demonstrated mainly in women who are postmenopausal since more than 5 years.
In the curative treatment of osteoporosis, calcium supplements should be regarded as an adjuvant treatment. The total daily requirements are of at least 1500 mg. Supplements are required within the frame of some specific treatments (fluoride, calcitonin, bisphosphonates).
VITAMIN D
Administration of vitamin D supplements to children, adolescents or premenopausal women, who are in good health, has no place in the prevention of postmenopausal osteoporosis. The same holds true for the prevention after the menopause. Administration of vitamin D in doses approaching the daily requirements (400 to 800 IU), concomitantly with calcium supplements, is justified in elderly people, especially when residing in nursing homes.
As to the treatment of osteoporosis, there are no studies pertaining to the use of native vitamin D alone. The 1-o~-hydroxylated derivatives have a limited positive effect on the bone mass. Inasmuch as a preventive effect on the occurrence of fractures has not been clearly established, their use remains experimental. As to date, it is not possible to affirm that the action of these derivatives on the bone differs from that of vitamin D. One should also take into account the potential toxicity (hypercalciuria, hypercalcemia) when pharmacological doses are being used.
HORMONAL REPLACEMENT THERAPIES
Hormonal replacement therapy is an effective therapeutic mean for the prevention of osteoporosis. The mean effective dose is 0.625 mg conjugated equine estrogens or 2 mg 17-13-estradiol, administered orally, or 50/x 17-[3-estradiol by transdermic route. Other estrogens or alternative routes of administration, resulting in an equivalent estrogen impregnation, are also justified. Moreover, hormonal replacement therapy has other beneficial effects (reduction of climacteric symptoms; possibly a decrease of cardiovascular mortality). The possibility of an increased risk of breast cancer as a consequence of hormonal replacement therapy, with or without a progestogen, has not been excluded. The risk of endometrial carcinoma can be prevented by association of a progestogen. The practical modalities of the therapy can influence the compliance, which often poses problems for this kind of treatment. In the curative treatment, estrogens still exert a protective effect on bone mass, but the risk/benefit ratio for this approach is not established.
CALCITONIN
Long-term administration of calcitonin, by parenteral or nasal route, can prevent postmenopausal trabecular bone loss. The optimal therapeutic regimen is yet to be established. A therapeutic benifit at the level of the cortical bone, which is well-documented for estrogens, has not been established for calcitonin.
In the curative treatment, calcitonin prevents further bone loss. The latter effect is especially pronounced when the level of bone turnover is high. Efficacy of calcitonin in preventing fractures has been reported on several occasions but remains to be confirmed. Calcitonin has analgesic properties.
BISPHOSPHONATES
The use of etidronate, a first generation bisphosphonate, in the prevention of osteoporosis is experimental
In the treatment of osteoporosis, the effect of etidronate has been studied only in populations already presenting with vertebral compression fractures. In those patients there is a positive effect on bone mass, but a reduction of the fracture incidence in the whole of that population has not been established. The suggestion, based on an "a posteriori" analysis, of a more pronounced beneficial effect obtained after 2 years in patients presenting with severe osteoporosis, remains to be confirmed. Whether this treatment is innocuous in the long run, is presently under study. The bisphosphonates of later generations remain experimental, both in the prevention and in the treatment.
FLUORIDE ASSOCIATED WITH CALCIUM
Treatment with fluoride and calcium has no place in the prevention of osteoporosis. This therapy should be reserved for the treatment of axial osteoporosis in patients with normal renal function. In this indication, this is the only therapy capable of increasing the trabecular bone mass during the whole duration of its administration. This effect is not necessarily accompanied by a proportional improvement of the biomechanical properties of the skeleton.
In order to limit the occurrence of mineralization defects, the daily dose should not exceed 50 mg of sodium fluoride (to be associated with i g of calcium) or 150 mg of sodium monofluorophosphate. The efficacy of the treatment in preventing fractures remains to be confirmed and is probably dependent on the applied therapeutic regimen. About one third of the cases are resistant to the treatment, mainly as a consequence of deficient intestinal absorption.
ANABOLIC STEROIDS
The anabolic steroids have no place in the prevention of osteoporosis.
As far as the treatment is concerned, there is no place for the 17-c~-alkylated derivatiyes, considering their hepatotoxicity. The 17-~-alkylate d derivatives, on the contrary, can be used in the treatment, but their pharmacologic properties (e.g. the effects on lipid metabolism, ...) limit their use to elderly patients. One should also take into account the occurrence of signs of virilization in 50% of cases after 1 year. These compounds increase the muscular mass, but their efficacy in preventing fractures has not been established.
OTHER DRUGS
Many compounds, such as ipriflavone, growth factors, strontium salts and parathyroid hormone are being studied. At this stage, their use remains experimental. It has been reported that tibolone influences favorably the bone mass, but at this stage its use is indicated neither in the prevention nor in the treatment of osteoporosis, inasmuch as the risk/benefit ratio has not been satisfactorily determined. Finally, the thiazides have no established place in either the prevention or the treatment of primary osteoporosis.
